
    
      Approximately 825 subjects will be enrolled and receive NeoVas BCS(Lepu Medical Technology
      (Beijing) Co.,Ltd). Subjects will have clinical follow-up at 30, 90, 180 and 270 days and at
      1,2,3,4 and 5 years. The primary endpoint is target lesion failure(TLF) at 1 year follow-up.
    
  